Integra LifeSciences Holdings Corporation (NASDAQ:IART) posted stronger-than-expected third-quarter earnings on Thursday, but revenue missed forecasts and the company lowered its forward guidance, sending shares down 2.79% in premarket trading.
The medical technology firm reported adjusted earnings of $0.54 per share, beating analyst expectations of $0.43, while revenue totaled $402.1 million, below the $414.23 million consensus. On a year-over-year basis, revenue rose 5.6% as reported and 5.0% on an organic basis.
“In the third quarter, we continued to see healthy demand across our portfolio. While revenue was impacted by two supply interruptions, we delivered strong profitability and cash flow through disciplined cost management and operational efficiencies,” said Mojdeh Poul, President and Chief Executive Officer.
The company’s Codman Specialty Surgical segment, which accounts for roughly 70% of total revenue, grew 8.1% year-over-year to $292.6 million. Meanwhile, the Tissue Technologies division declined slightly by 0.5% to $109.5 million.
Looking ahead, Integra issued weaker fourth-quarter guidance, projecting revenue between $420 million and $440 million, below analysts’ expectations of $456.2 million. The company also revised its full-year 2025 revenue outlook to $1.62–$1.64 billion, compared with the consensus estimate of $1.67 billion.
For earnings, Integra now anticipates adjusted EPS of $0.79–$0.84 for the fourth quarter, missing the $0.92 consensus, while full-year EPS of $2.19–$2.24 remains broadly in line with market forecasts.
“We are making progress in implementing our comprehensive plan to systematically strengthen the entirety of our supply chain and quality management system, and we remain confident in our strategy to improve overall performance and drive the company’s transformation,” Poul added.